Phase II
Abivax SA announced dosing of the first patient in a U.S. Phase 1/2 clinical trial of ABX196 to treat patients with hepatocellular carcinoma, the most common form of liver cancer..
With the acquisition of San Diego-based PvP Biologics and a recent deal with COUR Pharmaceuticals, Takeda Pharmaceutical is looking to become a world leader in the treatment of celiac disease and other gastrointestinal disorders.
A federal judge has ruled that a decade’s worth of unpublished clinical trial data from drug companies, universities and other agencies involved, must now be made public.
Data position the company to start potential registrational trials with two drugs in two tumor types
BioSpace takes a look at some of the investigational products that could, one day, provide relief for migraine sufferers.
Mid-February had a solid number of clinical trial announcements. Here’s a look.
Teva’s deutetrabenazine for the treatment of tics in pediatric patients with moderate to severe Tourette Syndrome did not meet the primary endpoint in the Phase II/III ARTISTS 1 and Phase III ARTISTS 2 trials.
Recardio Inc., a clinical-stage life science company, announced that it has completed an interim analysis of its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction.
The Phase II trial did not meet its primary endpoint.
The trial evaluated INOpulse for the treatment of Pulmonary Hypertension associated with Pulmonary Fibrosis (PH-PF).
PRESS RELEASES